Paxillin has been shown to be highly expressed in many malignant tumors and is frequently associated with progression and poor patient outcomes, as seen in gastric cancer [37], lung cancer [38,39], esophageal cancer [40], and colorectal cancer [41]. This evidence concerns the gene PXN and esophageal cancer.